Evidence map›Paper›PMID 40787538›Full record

ReviewAnnals of medicine and surgery (2012)2025

Exploring Cognitive Enhancers: from neurotherapeutics to ethical and regulatory challenges: a mini review.

Abdulbasit Opeyemi Muili, Adibi Victor Temilola, Oyekunle Olufunmike Itunu, Olanipekun Abdulazeez Olajide, Conteh Deborah Ngozi, Piel Panther Kuol

Abstract readReview
In one paragraph

Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Abdulbasit Opeyemi MuiliDepartment of Medicine, Ladoke Akintola University of Technology, Ogbomosho, Nigeria.
Adibi Victor TemilolaDepartment of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria.
Oyekunle Olufunmike ItunuDepartment of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria.
Olanipekun Abdulazeez OlajideDepartment of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria.
Conteh Deborah NgoziDepartment of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria.
Piel Panther KuolSchool of Medicine, Moi University, Kenya.ORCID https://orcid.org/0009-0003-2267-5375

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This manuscript provides an outlook on using cognitive enhancers and their ethical implications. Cognitive enhancers, including prescription medications like modafinil and methylphenidate, over-the-counter supplements such as ginseng and caffeine, and novel nootropic agents like gene therapy and stem cell interventions, improve cognitive functions such as memory, focus, and learning. While they have shown efficacy in treating neurodegenerative disorders like Alzheimer's disease and attention-deficit/hyperactivity disorder (ADHD), their growing use by healthy individuals raises ethical concerns. This paper addresses the benefits of cognitive enhancers, such as improved academic and professional performance, and the associated risks, including addiction, dependence, and long-term health consequences. It also delves into social and ethical issues, including disparities in access, fairness, coercion in competitive environments, and distinguishing between genuine and substance-enhanced achievements. Additionally, the paper examines current regulations and proposes stronger legal frameworks to address the increasing use of cognitive enhancers. In conclusion, while cognitive enhancers have potential therapeutic benefits, a balanced approach is needed to regulate their use and ensure they are not misused to gain unfair advantages, particularly in non-medical settings.

Indexed as

cognitiveethicalnootropic

Identifiers

PMID40787538
PMCPMC12333774

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.